Zimmer Biomet (ZBH)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$98.07-0.86%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · ZBH
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $98 ZBH trades at 12× p/e, below its 28× p/e peer median. Our $122 fair value sits above the price. We hold it with medium confidence: the peer anchor overstates how cheap it looks. Analysts target $93–$120. Note: our $122 fair value sits above the entire analyst range ($93–$120). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $104.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $132.36 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $185.05 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $16.70 | — | — | TTM | high |
| graham number | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$93.00 – $120.00 (median $104.00) · 9 analysts · as of 2026-08-10
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $111.81 |
| — |
| — |
| TTM |
| high |
| Peer EV/EBITDA | 12M | $41.74 | 6.2 | 12.69 | TTM | high |
| Peer P/FCF | 12M | $162.72 | 24.6 | 6.60 | TTM | high |
| Peer P/E | 12M | $166.43 | 18.7 | 8.89 | ntm analyst | high |
| Peer P/S | 12M | $129.91 | 2.9 | 44.13 | TTM | high |
| PEG | 12M | $205.68 | 24.3 | 8.48 | TTM | high |
| residual income | 12M | $77.15 | — | — | TTM | high |
| Own P/E history | 12M | $108.84 | 12.8 | 8.48 | TTM | high |
| triangulated | 12M | $246.39 | 28.3 | 8.72 | Triangulated | high |
| Peer P/FCF | 3Y | $202.55 | 24.6 | 8.22 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $180.20 | 18.7 | 9.63 | Analyst | medium |
| Peer P/S | 3Y | $144.47 | 2.9 | 49.08 | guidance | medium |
| PEG | 3Y | $233.57 | 24.3 | 9.63 | Analyst | medium |
| Own P/E history | 3Y | $123.60 | 12.8 | 9.63 | Analyst | medium |
| Peer P/FCF | 5Y | $234.38 | 24.6 | 9.51 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $193.04 | 18.7 | 10.32 | Analyst | high |
| Peer P/S | 5Y | $154.76 | 2.9 | 52.58 | guidance | high |
| PEG | 5Y | $250.20 | 24.3 | 10.32 | Analyst | high |
| Own P/E history | 5Y | $132.41 | 12.8 | 10.32 | Analyst | high |